

PRECEPTORSHIP PROGRAMME

Prostate Cancer

Multidisciplinary management, standards
of care and future perspectives

LUGANO
SWITZERLAND

11-12 NOVEMBER 2016

Chair Alan Horwich, UK
Co-Chair Winald Gerritsen, NL

ESMO PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
11-12 November 2016

CHAIR: Alan Horwich, United Kingdom
CO-CHAIR: Winald Gerritsen, Netherlands

SPEAKERS: Ferran Algaba, Spain
Elena Castro, Spain
Valérie Fonteyne, Belgium
Nicolas Mottet, France

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Luigi Taddei 4
6962 Lugano - Viganello
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 11 November 2016

09:00-09:15 15'	Opening and welcome	
15'	Welcome from ESMO - objectives and scientific introduction	Alan Horwich, UK
09:15-10:30 75'	Session 1 Screening, diagnosis and staging	Chairs: Alan Horwich, UK Valérie Fonteyne, BE
20'	PSA screening and diagnosis	Nicolas Mottet, FR
20'	Diagnosis and impact of pathology on prognosis	Ferran Algaba, ES
20'	Imaging tests and staging classification	Nicolas Mottet, FR
15'	Discussion	Faculty
10:30-11:00	Coffee Break	
11:00-12:30 90'	Session 2 Localized prostate cancer	Chairs: Ferran Algaba, ES Elena Castro, ES
20'	Role of radiotherapy	Valérie Fonteyne, BE
20'	Role of surgery	Nicolas Mottet, FR
20'	Active surveillance	Alan Horwich, UK
2x15'	2 x Participants clinical case discussion	Faculty
12:30-13:30	Lunch	
13:30-15:15 105'	Session 3 Locally-advanced prostate cancer	Chairs: Alan Horwich, UK Winald Gerritsen, NL
15'	Presentation with lymphadenopathy	Nicolas Mottet, FR
10'	Managing urinary obstruction	Nicolas Mottet, FR
	<u>Debate:</u> This house believes that locally-advanced prostate cancer should be treated with radiotherapy and hormone deprivation	
10'	Argument For	Valérie Fonteyne, BE
10'	Argument Against	Nicolas Mottet, FR
10'	Discussion	Faculty
20'	Value and role of PSA as a tumour marker of response/relapse	Elena Castro, ES
2x15'	2 x Participants clinical case discussion	Faculty
15:15-15:45	Coffee Break	
15:45-17:30 105'	Session 4 Initial systemic therapy	Chairs: Valérie Fonteyne, BE Winald Gerritsen, NL
30'	First-line hormone therapy for metastatic disease; role and toxicities	Alan Horwich, UK
30'	First and second-line chemotherapy	Elena Castro, ES
3x15'	3 x Participants clinical case discussion	Faculty
19:00	Dinner	

Saturday, 12 November 2016

09:00-10:30 90'	Session 5 Castration Resistant Prostate Cancer (CRPC)	Chairs: Elena Castro, ES Nicolas Mottet, FR
30'	Next generation androgen receptor axis inhibitors	Winald Gerritsen, NL
30'	Isotope therapies and palliative radiotherapy	Alan Horwich, UK
2x15'	2 x Participants clinical case discussion	Faculty
10:30-11:00	Coffee Break	
11:00-12:30 90'	Session 6 Novel therapies	Chairs: Alan Horwich, UK Elena Castro, ES
20'	Bone targeting (Bisphosphonates and RANK ligands)	Winald Gerritsen, NL
30'	Immunotherapy and other new drug targets	Winald Gerritsen, NL
10'	Discussion: sequencing of treatments	Faculty
2x15'	2 x Participants clinical case discussion	Faculty
12:30-12:45 15'	Conclusion and farewell	
12:45-13:45	Lunch	

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion